BC Week In Review | Jun 3, 2013
Clinical News

DSTP3086S: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 28 patients with CRPC showed that the recommended Phase II dose of IV DSTP3086S was 2.8 mg/kg given every 3 weeks. Dose-limiting toxicities (DLTs) of reversible grade...
Items per page:
1 - 1 of 1